Past Press Releases - Isarna Therapeutics (formerly Antisense Pharma)

May 21, 2015
Isarna Announces Orphan Drug Designation in the European Union for ISTH0036 to Treat Advanced-...
Isarna Announces Orphan Drug Designation in the European Union for ISTH0036 to Treat Advanced-Stage Glaucoma More

January 8, 2015
Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program ...
Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program Targeting Multiple Indications in Ophthalmology More

July 24, 2012
Antisense Pharma Receives FDA Orphan Drug Designation for Trabedersen to Treat Malignant Melanoma
TGF-β2 inhibitor has gained market exclusivity in the USA for a third aggressive cancer indication More

June 4, 2012
Antisense Pharma Presents Trabedersen Phase I/II Complete Data at ASCO
Trabedersen demonstrated excellent safety combined with encouraging survival in patients with advanced pancreatic cancer and malignant melanoma. More

July 6, 2011
Antisense Pharma completes round of financing worth approximately 8 million euro
Founding shareholders facilitate the participation of new investors. More

June 2, 2009
Antisense Pharma announces new data on its lead compound
Trabedersen shows good safety, tolerability and promising survival in patients with pancreatic carcinoma, malignant melanoma and colorectoral carcinoma. More

April 27, 2009
Antisense Pharma begins pivotal Phase III clinical trial with trabedersen in aggressive brain tumors
First patients enrolled in international SAPPHIRE study of recurrent or refractory anaplastic astrocytoma More

November 8, 2007
EUR 27 million venture capital for specialist in cancer therapeutics
Antisense Pharma GmbH, biotech leader in the development of targeted therapies for malignant tumors, receives venture capital amounting to EUR 27 million (USD 38 million) from the VC-funds of the MIG AG. More

November 8, 2007
EUR 27 million venture capital for specialist in cancer therapeutics
Antisense Pharma GmbH, biotech leader in the development of targeted therapies for malignant tumors, receives venture capital amounting to EUR 27 million (USD 38 million) from the VC-funds of the MIG AG. More

November 30, 2005
Antisense Pharma raises $ 18 Million in Venture Financing
Regensburg, November 30th, 2005 – Antisense Pharma announces today that it has raised $ 18.0 million in private equity from the German MIG funds. This investment further validates Antisense Pharma´s worldwide leadership in the field of antisense technology and its application, the development of targeted anticancer drugs. More